News | European Medicines Agency (EMA)
Seventeen new medicines recommended for approval; another eight medicines recommended for extension of their therapeutic indications
News and events | European Medicines Agency (EMA)
The European Medicines Agency's news announcements, information on meetings and events, public consultations and related information.
European Medicines Agency (EMA)
The European Medicines Agency is a decentralised agency of the European Union responsible for the evaluation, supervision and safety monitoring of medicines.
Cancer - European Medicines Agency (EMA)
The newest and recently updated medicines authorised for cancer in the European Union; EMA's latest cancer-related news announcements; EMA's upcoming events on cancer-related topics
Wainzua | European Medicines Agency (EMA)
European Commission decision Overview On 17 October 2024, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Wainzua 1 , intended for the treatment of adults with hereditary transthyretin-mediated amyloidosis (ATTRv) and stage 1 ...
What's new - European Medicines Agency (EMA)
Filters are available to narrow results down based on your interests, such as whether it relates to human or veterinary medicines or specific topics. This overview covers up to two months back. What's new - Menu tabs
RSS feeds - European Medicines Agency (EMA)
The European Medicines Agency's (EMA) RSS feeds allow you to stay up to date with the latest news and features you are interested in from this website.
Leqembi recommended for treatment of early Alzheimer’s disease
Nov 14, 2024 · After re-examining its initial opinion, EMA’s human medicines committee (CHMP) has recommended granting a marketing authorisation to Leqembi (lecanemab) for treating mild cognitive impairment (memory and thinking problems) or mild dementia due to Alzheimer’s disease (early Alzheimer’s disease) in patients who have only one or no copy of ...
Regulation on EMA’s extended mandate becomes applicable
Mar 1, 2022 · The Agency will also coordinate responses of EU / EEA countries to shortages of critical medical devices and in-vitro diagnostics in crisis situations, after an initial transition period up to 2 February 2023.
Newsletters - European Medicines Agency (EMA)
The European Medicines Agency (EMA) publishes newsletters to provide updates on various topics to patients, healthcare professionals and the pharmaceutical industry.
- Some results have been removed